


CLEAN VERSION OF AMENDED CLAIMS

1 1. (Currently amended) A composition for the treatment of proliferative
2 disorders, comprising an antineoplastic agent and a compound having the formula:



3
4 and pharmaceutically acceptable salts thereof;
5 wherein


6 R is a member selected from the group consisting of hydrogen
7 and substituted or unsubstituted (C₁-C₁₀)alkyl; and

8 Ar is a member selected from the group consisting of
9 substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

1 8. (Currently amended) A composition in accordance with claim 7,
2 wherein said substituents on said phenyl group are selected from the group consisting of
3 halogen, (C₁-C₄)alkoxy, (C₁-C₄)alkyl, -OPO₃H₂, -OC(O)R', -NR'R'', -CO₂R', -CONR'R'', -
4 C(O)R', -OC(O)NR'R'', -NR"C(O)R', -NR"C(O)₂R', -NR'-C(O)NR"R''', perfluoro(C₁-
5 C₄)alkoxy, and perfluoro(C₁-C₄)alkyl, wherein R', R'' and R''' is each independently
6 hydrogen or (C₁-C₄)alkyl.

1 17. (Currently amended) A method for the treatment of a proliferative
2 disorder, comprising administering to a subject in need of such treatment:
3 i) a first amount of an antineoplastic agent; and

4 ii) a second amount of a compound of formula:



5

6 and pharmaceutically acceptable salts thereof; wherein

7 R is a member selected from the group consisting of hydrogen and
8 substituted or unsubstituted (C₁-C₁₀)alkyl; and

9 Ar is a member selected from the group consisting of substituted or
10 unsubstituted aryl and substituted or unsubstituted heteroaryl;
11 wherein said first amount and said second amount, in combination, are effective to
12 treat said proliferative disorder.